Cordycepin

Catalog No.S3610 Synonyms: 3'-Deoxyadenosine

For research use only.

Cordycepin (3'-Deoxyadenosine) is an adenosine analogue, which is readily phosphorylated to its mono-, di-, and triphosphate intracellularly. It has a very potent anti-cancer, anti-oxidant and anti-inflammatory activities.

Cordycepin Chemical Structure

CAS No. 73-03-0

Purity & Quality Control

Choose Selective MMP Inhibitors

Other MMP Products

Biological Activity

Description Cordycepin (3'-Deoxyadenosine) is an adenosine analogue, which is readily phosphorylated to its mono-, di-, and triphosphate intracellularly. It has a very potent anti-cancer, anti-oxidant and anti-inflammatory activities.
In vitro

Cordycepin increases interleukin (IL)-10 expression, decreased IL-2 expression and suppresses T lymphocyte activity. It also up-regulates IL-1beta, IL-6, IL-8 and TNF-alpha and suppresses phytohemagglutinin (PHA)-induced production of IL-2, IL-4, IL-5, IFN-gamma and IL-12[1]. The structure of Cordycepin is very much similar with cellular nucleoside, adenosine and acts like a nucleoside analogue. Cordycepin lacks 3' hydroxyl group in its structure. It provokes RNA chain termination and interferes in mTOR signal transduction. At higher doses, Cordycepin inhibits cell attachment and reduces focal adhesion. under low nutritional stress, Cordycepin activates AMPK which blocks the activity of mTORC1 and mTORC2 complex. The inactivated mTORC2 complex cannot activate AKT 1 kinase fully, which in turn blocks mTOR signal transduction inhibiting translation and further cell proliferation and growth. Cordycepin also induces apoptosis by enhancing JNK and p38 kinase activity and increasing the protein expression of Bcl-2 pro-apoptotic molecules[2]. Cordycepin has anti-tumor effect on mouse melanoma and lung carcinoma cells and human oral cancer cells[3].

In vivo Orally administered cordycepin inhibits melanoma cell growth in mice with no adverse effects[4]. Oral cordycepin administration at dose of 10 mg/kg significantly improves Y-maze learning performance both in healthy and ischemic mice. However, cordycepin at dose of 5 mg/kg enhanced Y-maze learning only in ischemic mice but not healthy mice. Cordycepin significantly decreases the neuronal loss induced by ischemia in hippocampal CA1 and CA3 regions[5].

Protocol (from reference)

Cell Research:[3]
  • Cell lines: MA-10 cells
  • Concentrations: 10 μM, 100 μM, 1 mM, 2 mM and 5 mM
  • Incubation Time: 24 h
  • Method: MA-10 cells (6 × 105) are seeded in 6-cm Petri dish with 2 mL serum medium. After 70-80% confluence, cells are treated without or with 10 μM, 100 μM, 1 mM, 2 mM and 5 mM cordycepin for 24 h. Cell morphology is then observed and recorded under light microscopy. Apoptosis is characterized by the loss of cellular contact with the matrix and the appearance of plasma membrane blebbing.
  • (Only for Reference)
Animal Research:[4]
  • Animal Models: C57BL/6Cr mice
  • Dosages: 5 and 15 mg/kg
  • Administration: oral
  • (Only for Reference)

Solubility (25°C)

In vitro

DMSO 50 mg/mL
(199.01 mM)
Water 25 mg/mL
(99.5 mM)
Ethanol 1 mg/mL
(3.98 mM)

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 251.24
Formula

C10H13N5O3

CAS No. 73-03-0
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1C(OC(C1O)N2C=NC3=C(N=CN=C32)N)CO

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00709215 Unknown status Drug: Cordycepin plus Pentostatin Refractory TdT-Positive Leukemia OncoVista Inc.|AAIPharma June 2008 Phase 1|Phase 2

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Cordycepin | Cordycepin supplier | purchase Cordycepin | Cordycepin cost | Cordycepin manufacturer | order Cordycepin | Cordycepin distributor